

MedStar Health

Advances in Urologic Oncology 2026



October 16 to 17, 2026
Park Hyatt | Washington, D.C.

Course directors:

Michael B. Atkins, MD

Georgetown Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Washington, D.C.

Keith J. Kowalczyk, MD

MedStar Georgetown University Hospital
Georgetown University Medical Center
Washington, D.C.

Mohit Gupta, MD

MedStar Georgetown University Hospital
Washington, D.C.

Jonathan W. Lischalk, MD

Georgetown Lombardi Comprehensive Cancer Center
Washington, D.C.

Lambros Stamatakis, MD

MedStar Washington Hospital Center
Washington, D.C.

Nicholas Simon, MD

MedStar Washington Hospital Center
Washington, D.C.

Continuing education credit information

Course description

The **MedStar Health Advances in Urologic Oncology 2026** conference is a two-day educational event designed for healthcare professionals involved in the diagnosis, treatment, and management of urologic cancers. The conference covers the latest advancements in prostate, bladder, and kidney cancers through lectures, interactive case-based tumor boards with audience polling, panel debates, and presentations from nationally recognized faculty. Attendees will gain practical knowledge of emerging therapies, evolving treatment paradigms, and value-based care considerations that can be applied directly to clinical practice.

Prostate Cancer: The prostate cancer sessions will cover advancements in diagnosis, local treatment, radiation, systemic therapy, and survivorship. Topics include the evolving role of genomic classifiers in guiding treatment decisions and personalizing management, advances in PSMA PET imaging and its impact on staging and treatment planning, and emerging techniques in transperineal biopsy. The expanding landscape of local treatment options will be explored, including focal therapy modalities, neoadjuvant radioligand therapy before radical prostatectomy, and surgical advances in functional outcomes. Modern radiation approaches will be addressed, including SBRT and ultra-hypofractionation, focal dose escalation, de-escalation strategies aimed at reducing toxicity while maintaining outcomes, and the integration of genomic classifiers and PSMA imaging into radiation treatment planning. The evidence for pelvic nodal irradiation in high-risk disease and the role of metastasis-directed SBRT for oligometastatic disease will also be reviewed.

Systemic therapy sessions will cover treatment intensification in metastatic hormone-sensitive disease, sequencing through castration-resistant disease, and PSMA-guided salvage strategies for biochemical recurrence. ADT survivorship topics including bone health, cardiovascular risk, and sexual health will be discussed. The day will close with a faculty debate on the role of pelvic lymph node dissection in the era of molecular imaging, followed by a session examining the cost, access, and equity implications of the innovations presented, helping attendees put new technologies and treatments into practical perspective.

Bladder Cancer: Bladder cancer management has seen significant advancements with the introduction of novel intravesical therapies and systemic treatments. The conference will provide clarity on treatment strategies for non-muscle invasive bladder cancer (NMIBC), including approaches for intermediate- and high-risk disease, surveillance and escalation pathways, and the expanding therapeutic options for BCG-unresponsive patients. Updates on the evolving perioperative treatment paradigm for muscle-invasive bladder cancer will be reviewed, including novel antibody-drug conjugate and immunotherapy combinations. The role of cystectomy versus bladder preservation strategies will be discussed, along with patient selection and quality-of-life considerations. The growing role of circulating biomarkers, including ctDNA and utDNA, will be reviewed for their application in surveillance, risk stratification, and perioperative decision support. The metastatic urothelial cancer treatment continuum will be explored, with sessions covering frontline and later-line sequencing strategies including antibody-drug conjugates, targeted therapies, and immunotherapy. A dedicated session on upper tract urothelial carcinoma will address risk stratification, kidney-sparing approaches, endoscopic management, intraluminal therapies, molecular profiling, and surgical decision-making.

Kidney Cancer: Kidney cancer, particularly renal cell carcinoma (RCC), presents significant challenges in both diagnosis and treatment. Sessions will cover management of the small renal mass, the role and timing of cytoreductive nephrectomy in metastatic disease, and advances in adjuvant immunotherapy for high-risk localized RCC. Strategies for managing metastatic RCC will be addressed, including first-line combination regimen selection, subsequent-line therapy sequencing, and emerging imaging modalities. A dedicated session on non-clear cell RCC will cover histology-driven treatment approaches for less common subtypes.

For updated information, visit [MedStarHealth.org/AdvancesInUrologicOncology](https://www.MedStarHealth.org/AdvancesInUrologicOncology)

Continuing education credit information

Multidisciplinary Care: The integration of multidisciplinary care is essential for optimizing patient outcomes in urologic oncology. The conference features interactive tumor boards with audience polling after every major clinical block, ensuring attendees engage with real cases across prostate, bladder, and kidney cancers in a collaborative format. A closing co-management panel will address the practical question of when the community urologist should treat, when to refer, and how to co-manage patients receiving systemic therapy across all three disease states.

Learning objectives

- **Prostate Cancer Diagnosis and Imaging:** Describe the role of PSMA PET imaging and transperineal biopsy techniques in diagnosing and staging prostate cancer, and how imaging findings guide treatment decisions across surgical, radiation, and systemic therapy pathways.
- **Genomic and Biomarker-Guided Decision-Making:** Evaluate the current and emerging genomic classifiers and biomarker tools for assessing prostate cancer risk, guiding active surveillance decisions, and personalizing treatment selection across risk categories.
- **Localized Prostate Cancer Treatment Options:** Compare the efficacy and suitability of focal therapy, surgical approaches, and radiation techniques including SBRT, ultra-hypofractionation, and focal dose escalation, incorporating evidence for de-escalation strategies that maintain outcomes while reducing toxicity.
- **Neoadjuvant and Novel Therapeutic Strategies:** Discuss the rationale and emerging evidence for neoadjuvant radioligand therapy before radical prostatectomy and its implications for high-risk localized prostate cancer management.
- **Management of Advanced and Metastatic Prostate Cancer:** Discuss the latest approaches in systemic treatment of metastatic prostate cancer, including treatment intensification, PSMA-guided salvage strategies for biochemical recurrence, and sequencing through castration-resistant disease.
- **Radiation Advances in Prostate Cancer:** Analyze modern radiation approaches including pelvic nodal irradiation for high-risk disease, metastasis-directed SBRT for oligometastatic disease, and how genomic classifiers and molecular imaging are being integrated into radiation treatment decisions.
- **Non-Muscle Invasive Bladder Cancer Therapeutics:** Assess treatment strategies for intermediate- and high-risk NMIBC, including surveillance and escalation pathways, and evaluate the expanding therapeutic options for BCG-unresponsive disease.
- **Muscle-Invasive and Metastatic Bladder Cancer Management:** Discuss the evolving perioperative treatment paradigm for muscle-invasive bladder cancer, evaluate cystectomy versus bladder preservation approaches, and apply sequencing strategies across the metastatic urothelial cancer treatment continuum.
- **Kidney Cancer Management:** Identify appropriate management strategies for small renal masses, evaluate the role and timing of cytoreductive nephrectomy, and discuss the implications of adjuvant immunotherapy for high-risk localized RCC.
- **Advanced and Non-Clear Cell RCC:** Discuss first-line and subsequent-line treatment decision-making in metastatic RCC and apply histology-driven treatment approaches for non-clear cell subtypes.
- **Multidisciplinary Case Analysis:** Analyze management strategies for complex clinical scenarios through interactive multidisciplinary tumor boards across prostate, bladder, and kidney cancers.
- **Value-Based Care and Co-Management:** Evaluate the cost, access, and equity implications of emerging urologic oncology treatments, and apply a practical framework for when to treat, refer, or co-manage patients receiving systemic therapy.
- Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with urologic malignancies.

Continuing education credit information

Target audience

This conference is intended for physicians, residents and fellows, physician assistants, nurse practitioners, nurses, allied health professionals, medical oncologists, oncologists, pathologists, radiation oncologists, radiologists, surgeons, urologists, and other members of the healthcare team interested in the management of prostate, kidney, bladder, and testicular cancers.

Accreditation



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit designation



IPCE CREDIT™

This activity was planned by and for the healthcare team and learners will receive 12.75 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 12.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



American Board of Internal Medicine MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



American Board of Surgery CC Credit: Successful completion of this CME activity, which includes participation in the evaluation and quiz component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

MOC Participation Threshold: Learner participates by completing a quiz with feedback and references to additional learning. The learner must pass the quiz with an 80% or higher to receive credit.

Nurses: This activity is approved for 12.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

The agenda and credits available are subject to change.

Attention physician learners: To ensure accurate CME credit data reporting to participating state medical licensing boards/certifying boards, please log into CloudCME and click on My CE / Profile to review and update your profile with the following details: your full name, state of licensure (including number and expiration date), and your birth month and day. Additionally, please remember to check the box at the bottom of the profile screen to grant permission for us to report your completion data to ACCME and participating licensing/certifying boards. **Questions?** Email medstarceapplications@email.sitel.org

Course directors



Michael B. Atkins, MD

Deputy Director, Georgetown Lombardi Comprehensive Cancer Center
Staff Physician, Division of Hematology/Oncology
Professor and Vice Chair, Department of Oncology
MedStar Georgetown University Hospital
Georgetown University School of Medicine
Washington, D.C.



Mohit Gupta, MD

Director, Urologic Oncology
Urologic Oncologist
Associate Professor of Urology
MedStar Georgetown University Hospital
Georgetown University School of Medicine
Washington, D.C.



Keith J. Kowalczyk, MD

Physician Executive Director
Chair, Department of Urology
Chair, MedStar Robotic Surgery Service Line
MedStar Georgetown University Hospital
Georgetown University Medical Center
Washington, D.C.



Jonathan W. Lischalk, MD

Radiation Oncologist
MedStar Georgetown University Hospital
Associate Professor of Medicine
Georgetown University Medical Center
Washington, D.C.




Nicholas Simon, MD

Medical Oncologist, Genitourinary Oncology
MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Washington, D.C.



Lambros Stamatakis, MD

Director, Urologic Oncology
MedStar Washington Hospital Center
Assistant Professor of Urology
Georgetown University School of Medicine
Washington, D.C.



Faculty

Pedro C. Barata, MD, MSc, FACP

Director, Genitourinary Medical Oncology Research Program
University Hospitals Seidman Cancer Center
Case Western Reserve University
Cleveland, OH

Elias Chandran, MBBS, FRACP

Medical Oncologist, Assistant Research Physician
National Cancer Institute
National Institutes of Health
Bethesda, MD

Rohann Correa, MD, PhD, FRCPC

Radiation Oncologist & Chair
Genitourinary Disease Site Team
London Health Sciences Centre
London, Canada

Christopher P. Dall, MD

Urologic Oncology Fellow
Mass General Brigham
Boston, MA

Faculty

Benjamin J. Davies, MD

Professor of Urology
University of Pittsburgh School of Medicine
Pittsburgh, PA

Jillian Egan Kelly, MD

Assistant Professor
Albany Medical Center
Albany Med Health System
Albany, New York

Behfar Ehdaie, MD

Associate Professor
Department of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

Samson W. Fine, MD

Attending Urologic Pathologist
Memorial Sloan Kettering Cancer Center
New York, NY

Arvin George, MD

Director, Prostate Cancer Programs
Associate Professor, Clinical Urology
Johns Hopkins University School of Medicine
Baltimore, MD

Saby George, MD, FACP

Professor of Medicine and Oncology
Roswell Park Comprehensive Cancer Center
The Jacobs School of Medicine
The State University of New York (SUNY)
Buffalo, NY

Pooja Ghatalia, MD

Associate Professor, Department of Hematology/Oncology
Collaborating Member, Cancer Epigenetics
Nuclear Dynamics and Cancer Research Program
Fox Chase Cancer Center, Temple Health
Philadelphia, PA

Jim C. Hu, MD, MPH

Professor of Urology
Weill Cornell Medicine
Cornell University
New York, NY

Gopa Iyer, MD

Associate Attending Physician
Section Head, Urothelial Cancer
Memorial Sloan Kettering Cancer Center
New York, NY

Vadim S. Koshkin, MD

Associate Professor, Clinical Medicine
University of California San Francisco
San Francisco, CA

Jonathan Leeman, MD

Associate Professor
Harvard Medical School
Department of Radiation Oncology
Mass General Brigham
Boston, MA

Anand Mahadevan, MD, FRCS, FRCR

Professor, Radiation Oncology
NYU Grossman School of Medicine
Director, Stereotactic Radiation
Laura and Isaac Perlmutter Cancer Center at
NYU Langone Health
Chief of Service, Radiation Oncology
NYCHHC Bellevue Hospital
New York, NY

Todd M. Morgan, MD

Professor, Urology
Division Chief, Urologic Oncology
University of Michigan Medical School
Ann Arbor, MI

Himanshu Nagar, MD, MS

Director, Genitourinary Program
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Scot N. Niglio, MD

Genitourinary Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Channing Paller, MD

Professor, Oncology
Director, Prostate Cancer Clinical Research
Associate Director, Oncology
John Hopkins Clinical Research Network
Baltimore, MD

Michael Serzan, MD

Medical Oncologist
Dana Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Boston, MA

Armene K. Smith, MD

Associate Professor, Urology
Johns Hopkins University
Washington, D.C.

Alberto Vargas, MD

Genitourinary Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Nitin Yerram, MD

Director, Urologic Oncology
Director, Urologic Research
Assistant Professor, Hackensack-Meridian
School of Medicine
Department of Urology
Hackensack University Medical Center
Hackensack, NJ

Agenda | DAY ONE | PROSTATE CANCER

7:30 a.m. Registration & Continental Breakfast

8:15 a.m. Welcome & Course Overview
Course Directors

SESSION I: DIAGNOSTICS & STAGING

8:25 a.m. Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in 2026: How It Changes Staging & Management
Alberto Vargus, MD

8:45 a.m. Transperineal Biopsy: New Standard of Care?
Jim C. Hu, MD, MPH

9:05 a.m. Pathology That Matters: Volume Gleason 4, Cribriform & What's Actionable
Samson W. Fine, MD

9:25 a.m. Active Surveillance in Intermediate-Risk: How to Do It Safely
Behfar Ehdai, MD

9:45 a.m. Break

10:00 a.m. KEYNOTE: Genomics & Biomarkers That Actually Change Prostate Cancer Decisions
Todd M. Morgan, MD

SESSION II: LOCAL MANAGEMENT

10:45 a.m. Focal Therapy in 2026: Transurethral Ultrasound Ablation (TULSA), High-Intensity Focused Ultrasound (HIFU), Cryoablation, Irreversible Electroporation (IRE) & Stereotactic Body Radiation Therapy (SBRT)
Arvin George, MD

11:05 a.m. Surgical Advances in Localized Prostate Cancer
Keith J. Kowalczyk, MD

11:25 a.m. Neoadjuvant Therapy for High-Risk Prostate Cancer
Nitin Yerram, MD

11:50 a.m. Lunch Break and Visit the Exhibits

12:10 p.m. Lunch Symposium: Management and Treatment of Biochemically Recurrent Prostate Cancer
Nancy Dawson, MD

Sponsored by Astellas Pharma

This symposium is not certified for continuing education credit.

12:55 p.m. Dessert Break and Visit the Exhibits

SESSION III: RADIATION PERSPECTIVES

1:15 p.m. Radiation Update: SBRT, Hypofractionation & Post-Prostatectomy Salvage
Jonathan W. Lischalk, MD

1:35 p.m. Oligometastatic Prostate Cancer: SBRT & Metastasis-Directed Therapy
Rohann Correa, MD, PhD, FRCPC

1:55 p.m. Pelvic Nodal Radiation Therapy (RT) in High-Risk Prostate Cancer
Himanshu Nagar, MD, MS

2:15 p.m. Tumor Board: High-Risk, PSMA-Faint Pelvic Node and Rib Lesion — What's the Play?
R. Correa, MD; J. Lischalk, MD; H. Nagar, MD

2:40 p.m. Break

SESSION IV: RECURRENCE & ADVANCED DISEASE

2:55 p.m. Biochemical Recurrence: Evaluation & PSMA-Guided Salvage Pathways
Jonathan Leehman, MD

3:15 p.m. Systemic Therapy Update: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Triplets Through Metastatic Castration-Resistant Prostate Cancer (mCRPC) Sequencing
Channing Paller, MD

3:35 p.m. **KEYNOTE: Putting It All in Perspective: Value, Cost & Access in Prostate Cancer**
Benjamin J. Davies, MD

3:55 p.m. **Closing Remarks and Adjournment**
Course Directors

4:00 p.m. **Exhibitor Networking Reception**

Agenda | DAY TWO | BLADDER & KIDNEY CANCER

7:30 a.m. **Registration & Continental Breakfast**

8:15 a.m. **Day Two Welcome**
Course Directors

SESSION V: BLADDER: NON-MUSCLE INVASIVE

8:25 a.m. **Intermediate-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Standard & Emerging Therapeutics**
Mohit Gupta, MD

8:45 a.m. **High-Risk NMIBC: Surveillance Strategy & When to Escalate to Cystectomy**
Lambros Stamatakis, MD

9:05 a.m. **Bacillus Calmette-Guérin (BCG)-Unresponsive NMIBC: Prioritizing Patients in a Crowded Field**
Jillian Egan Kelly, MD

9:25 a.m. **Tumor Board: NMIBC — Escalation vs. Continued Intravesical Therapy**
J. Egan Kelly, MD; M. Gupta, MD; L. Stamatakis, MD

9:50 a.m. **Break**

SESSION VI: BLADDER: MUSCLE-INVASIVE & PERIOPERATIVE

10:05 a.m. **Muscle-Invasive Bladder Cancer (MIBC): Cystectomy vs. Bladder Preservation — Who Gets What in 2026?**
Christopher P. Dall

10:25 a.m. **Perioperative Systemic Therapy for MIBC**
Elias Chandran, MD

10:45 a.m. **Biomarkers in Bladder Cancer: Circulating Tumor DNA (ctDNA) & Urinary Tumor DNA (utDNA) for Monitoring & Decisions**
Pooja Ghatalia, MD

11:05 a.m. **Tumor Board: Perioperative MIBC — Navigating the New Landscape**
E. Chandran, MD; C. Dall, MF; P. Ghatalia, MD

11:30 a.m. **Lunch**

SESSION VII: BLADDER: METASTATIC DISEASE & UPPER TRACT

12:25 p.m. **Frontline Metastatic Urothelial Cancer: The Changing Paradigm**
Gopa Iyer, MD

12:45 p.m. **Later-Line Metastatic Urothelial Cancer: Sequencing After Progression**
Vadim S. Koshkin, MD

1:05 p.m. **Upper Tract Urothelial Carcinoma: Neoadjuvant vs. Adjuvant Therapy, Antibody-Drug Conjugate (ADC)/Immunotherapy (IO)**
Scot Niglio, MD

1:25 p.m. **Case Vignette: Metastatic Urothelial — Progressing Through First-Line, What's Next?**
V. Koshkin, MD; G. Iyer, MD; S. Niglio, MD

1:40 p.m. **Break**

SESSION VIII: KIDNEY

1:55 p.m.	Stereotactic Body Radiation Therapy (SBRT) for Small Renal Masses Anand Madhavan, MD, FRCS, FRCR	3:30 p.m.	Metastatic RCC: First-Line Through Subsequent-Line Decision-Making Michael B. Atkins, MD
2:15 p.m.	Cytoreductive Nephrectomy: Timing & Role in Metastatic Renal Cell Carcinoma (RCC) Armine K. Smith, MD	3:50 p.m.	Subsequent Treatment for Metastatic RCC Saby George, MD
2:35 p.m.	Adjuvant Therapy for High-Risk Localized RCC Michael Serzan, MD	4:10 p.m.	Treatment of Non-Clear Cell RCC Pedro C. Barata, MD, MSc, FACP
2:55 p.m.	Tumor Board: Post-Nephrectomy High-Risk — Adjuvant vs Surveillance A. Madhavan, MD; M. Serzan, MD; A. Smith, MD	4:30 p.m.	Panel Discussion: Future Directions for Treatment of Metastatic Kidney Cancer M. Atkins, MD; P. Barata, MD; S. George, MD
3:15 p.m.	Break	5:00 p.m.	Closing Remarks Course Directors



Registration information

REGISTRATION TYPE

Physician	\$150
Resident or Fellow	COMPLIMENTARY
Physician Assistant	\$75
Nurse Practitioner	\$75
Nurse	\$75
Allied Health Professional	\$75
Medical Student	COMPLIMENTARY
Industry Professional	\$225
One-Day Pass	\$90

Online registration


Please visit [MedStarHealth.org/AdvancesInUrologicOncology](https://www.MedStarHealth.org/AdvancesInUrologicOncology) for updated program and registration information. If you have questions or do not receive an email confirmation within 1-2 business days, please contact us at medstarcpe@medstar.net or (833) 731-1273.

Cancellation policy

Cancellations made in writing by September 11, 2026 will be subject to a 50% penalty. No refunds will be given after September 11, 2026. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Venue information

Park Hyatt Washington, DC
1201 24th St NW, Washington, DC 20037



For grant information please contact **Ada Guo** at ada.guo@medstar.net
For exhibit support information please contact **Elizabeth Romano** at elizabeth.s.romano@medstar.net